### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

LIGAND PH Form 4	IARMACEUTIC	ALS INC	<u> </u>									
July 07, 2005	5											
FORM	ΙΔ										APPROV	AL
	STATES	SECURITIES AND EXCHANGE C Washington, D.C. 20549					NGE	COMMISSIO	N OMB Number:	3235	-0287	
Check thi if no long subject to Section 1 Form 4 o	1ENT OF	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Estimated burden ho	Estimated average burden hours per		
Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										0.0		
(Print or Type F	Responses)											
1. Name and A MERTES T		2. Issuer Name <b>and</b> Ticker or Trading Symbol LIGAND PHARMACEUTICALS INC [LGND]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last) 10275 SCIE		3. Date of Earliest Transaction (Month/Day/Year) 07/05/2005				Director 10% Owner X_ Officer (give title Other (specify below) V-P, Controller & Treasurer						
	4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person							
SAN DIEGO	O, CA 92121								Form filed by Person	More than One	Reporting	
(City)	(State)	(Zip)	Tab	ole I - Non-	-De	erivative	Securi	ities A	cquired, Disposed	of, or Benefici	ally Owne	ed
	2. Transaction Date (Month/Day/Year)	Execution I any	Date, if	Code (Instr. 8)	TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) (A) or		)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature Indirect Benefici Ownersh (Instr. 4)	al hip	
Reminder: Ren	ort on a separate line	for each cla	iss of sec	Code V			(D) ned dir					
Kennider, Kep	on on a separate line			unues delle	CIIC	Perso inforn requir	ns wh nation red to iys a c	o res cont respo	pond to the colle ained in this form and unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securitie
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

#### Edgar Filing: LIGAND PHARMACEUTICALS INC - Form 4

(Instr. 3)	Price of Derivative Security		(Montl	n/Day/Year)	(Instr. 8)	or Dispos (D)	(Instr. 3, 4,				
					Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amou or Numb of Sha
Employee Stock Option (right to buy)	\$ 7.25	07/05/2005			А	15,000		01/05/2006 <u>(1)</u>	07/05/2015	Common Stock	15,0
Reporting Owners											
<b>Reporting Owner Name / Address</b>			Director	10% Owner		<b>tionships</b> r		Oth	er		

V-P, Controller & Treasurer

#### MERTES TOD 10275 SCIENCE CENTER DRIVE SAN DIEGO, CA 92121

## **Signatures**

By: Barbara J. Olson For: Tod G. Mertes

07/07/2005

\*\*Signature of Reporting Person

Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 7/5/05.
- (2) No price applies.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.